Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.03.23.713195

Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesions

Abstract

Multiple myeloma (MM) is a plasma cell malignancy shaped by dynamic interactions between MM cells and non-malignant cells in the immune microenvironment. To spatially profile the influence of cellular context on MM and immune cell expression, we developed a multimodal framework integrating 10x Genomics Visium HD, 10x Genomics Xenium, and clinically annotated single-cell RNA (scRNA-seq) sequencing datasets. Visium HD enabled unbiased, whole transcriptome, spatial discovery at 16 {micro}m resolution, Xenium provided orthogonal validation at single-cell resolution, and scRNA-seq extended findings by mapping spatial labels and leveraging the greater sequencing depth. We developed a custom framework for cell type annotation within Visium HD spatial bins. Our approach enabled identification of plasma cell-dense niches enriched for non-canonical Wnt signaling, associated with gene expression supporting cell adhesion mediated drug resistance, inferior progression-free survival, and extramedullary lesions. Immune cells within these neighborhoods exhibited suppressed transcriptional states, including increased inhibitory receptor expression such as LAG3. Utilizing the niche-driven transcriptional states in MM and immune cells, we were able to develop a 15-gene signature independently predictive of progression free survival (HR = 2.00, p < 0.0001). Collectively, this study demonstrates the potential of integrated spatial and single-cell transcriptomics to define niche-specific programs supporting MM progression.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ohlstrom, D. J., Michaud, M., Bakhtiari, M., Vieira Dos Santos, J., Pilcher, W. C., Staub, A., Satpathy, S., Ferguson, K., Mantrala, S., Kim-Schulze, S., Chen, Z., Lonial, S., Kemp, M. L., Sherbenou, D., Lagana, A., Jaye, D. L., Nooka, A., Parekh, S., Bhasin, M.. 2026-03-25. Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesions. https://doi.org/10.64898/2026.03.23.713195

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Minor intron splicing restricts E2F transcription factor activity in RB-deregulated prostate cancer

Castration-resistant prostate cancer with neuroendocrine differentiation (CRPC-NE) arises in RB1-mutated lineage plastic cells in response to androgen receptor (AR)-targeted therapies. RB1 loss leads to constitutive E2F activation and cylin-dependent kinase (CDK) inhibitor resistance, making it challenging to restrict E2F activity. A post-transcriptional node is that typical E2Fs contain a rare but highly conserved minor intron, processed by the minor spliceosome (MiS). In an in vivo CRISPR screen, we nominate the MiS as the strongest dependency, and U6atac correlates strongest with E2F transcriptional programs in a clinical CRPC cohort. U6atac depletion led to mis-splicing of typical E2Fs, cell cycle arrest, and translation of a minor intron-containing E2F1 isoform (E2F1-MIRI) as a pharmacodynamic biomarker. Combined E2F activator depletion, induced further neuroendocrine (NE) specification. U6atac depletion shifted NE identity along the ASCL1 axis without the secretory granule program, and induced cell-surface antigens including DLL3, nominating MiS inhibition as a combination partner for antigen-directed agents.

cancer biology↗

An expanded, phenotypically distinct tumor cell subset with low HPV mRNA increases recurrence risk

Human papillomavirus-related (HPV+) cancers harbor a subset of tumor cells expressing certain senescence-related transcripts and reduced levels of HPV mRNAs. We aimed to define this HPV-low population's biologic traits and clinical significance via integrated analysis of recurrence-prone human HPV+ oropharyngeal cancers (OPCs) and patient-derived xenografts (PDXs) of variable therapy sensitivity. Single-cell mRNA sequencing of PDXs and human tumors detected gene expression profiles in HPV-low cells indicating lack of senescence or terminal differentiation and intact tumorigenic capacity. HPV-low cells in cisplatin-refractory PDXs and particular human OPCs differentially upregulated multiple pathways linked to aggressive tumor biology, including RAS signaling, IL-6 signaling, and EMT. Predicted loss of cell-cell interactions among HPV-low cells reflected reduced epithelial identity, further supporting their more aggressive biology. Accordingly, the size of the pre-treatment HPV-low fraction had strong, independent association with recurrence risk. Genetic subclones within OPCs varied widely in content of HPV-low cells, which were enriched in particular lineages. Our findings uncover novel pro-tumor functions of HPV-low cells and support a central role for them in therapy resistance as well as potential utility as a clinical biomarker. Further elucidating mechanisms of cooperativity and plasticity between HPV-low and high states holds promise to reveal targets in treatment-refractory HPV+ malignancies.

cancer biology↗

Discovery of molecular glues for modulating MHC presentation of cancer neoantigens

Antigen presentation by MHC class I molecules is essential for cancer immunosurveillance, but many cancer-specific antigens fail to form complexes with Class I MHC and are poorly presented on the cell surface. In this study, we present a chemical strategy to overcome this limitation by identifying peptide MHC glues (PMGs) that promote the formation of peptide-MHC complexes with otherwise unpresentable cancer antigens. Crystal structures of these complexes show that our compounds stabilize antigen-MHC binding by making simultaneous interactions with the MHC protein and the antigen peptides. These findings reveal a new approach for chemically rewiring Class I MHC antigen presentation and accessing rare cancer antigens for therapeutic targeting.

cancer biology↗